Exelon is a drug marketed by Novartis and is included in three NDAs. It is available from four suppliers. There are three patents protecting this drug and four Paragraph IV challenges.
The generic ingredient in EXELON is rivastigmine tartrate. There are twenty-seven drug master file entries for this compound. Three suppliers are listed for this compound. There are two tentative approvals for this compound. Additional details are available on the rivastigmine tartrate profile page.
|Suppliers: see list||4|
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||Type||RLD||Patent No.||Patent Expiration||Product||Substance||Delist Req.||Exclusivity Expiration|
|CAPSULE; ORAL||020823||Apr 21, 2000||RX||Yes||5,602,176||<disabled>||<disabled>|
|FILM, EXTENDED RELEASE; TRANSDERMAL||022083||Jul 6, 2007||RX||Yes||<disabled>||<disabled>|
|FILM, EXTENDED RELEASE; TRANSDERMAL||022083||Jul 6, 2007||RX||No||6,335,031||<disabled>||Y||<disabled>|
|SOLUTION; ORAL||021025||Apr 21, 2000||RX||Yes||4,948,807||<disabled>||Y||<disabled>|
|FILM, EXTENDED RELEASE; TRANSDERMAL||022083||Jul 6, 2007||RX||Yes||6,316,023||<disabled>||Y||<disabled>|
|This preview shows a limited data set|
Subscribe for full access, or try a free trial
Export unavailable in trial.
Subscribe for complete access.
|rivastigmine||Transdermal System Extended-release||13.3 mg/24 hr||Exelon||1/22/2013|
|rivastigmine||Transdermal System Extended-release||4.6 mg/24 hr and 9.5 mg/24 hr||Exelon Patch||4/27/2011|
|rivastigmine tartrate||Oral Solution||2 mg/mL||Exelon||11/5/2004|
|rivastigmine tartrate||Capsules||1.5 mg, 3 mg, 4.5 mg and 6 mg||Exelon||4/21/2004|
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.